Cirius Therapeutics Highlights CIR-0602K as Promising New Therapy for Type 2 Diabetes
GRAND RAPIDS, Mich., June 1, 2026 Cirius Therapeutics has announced the presentation of new clinical data supporting CIR-0602K, its...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
GRAND RAPIDS, Mich., June 1, 2026 Cirius Therapeutics has announced the presentation of new clinical data supporting CIR-0602K, its...
